ERBB2 and breast adenocarcinoma: Baldueva et al. [187] demonstrated that oral melatonin supplementation improved the efficacy and the antitumor response to chemotherapy regimens including cyclophosphamide, adriamycin, 5-FU, and docetaxel, in HER2/neu transgenic mice model with spontaneous mammary adenocarcinomas; these therapies had been shown to be ineffective perhaps related to the inapropriate time of administration.